Journal: Cancer Reports

Article Title: Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models

doi: 10.1002/cnr2.1701

Figure Lengend Snippet: IL13Rα2 expression in castration‐resistant and ‐sensitive PDX tumors.A. Sequential changes in tumor size of a castration‐resistant PDX model (KUCaP7) and a castration‐sensitive PDX model (KUCaP10) in castrated (castration+) and control (castration−) mice ( n = 5 each) (* p < 0.05). B. IL13RA2, AR, and KLK3 mRNA expression (based on GAPDH) in KUCaP7 and KUCaP10 tumors detected by real‐time PCR (* p < 0.05, ** p < 0.005). C. Expression levels of IL13Rα2, AR, and PSA (based on α‐tubulin) in KUCaP7 and KUCaP10 tumors detected by western blotting

Article Snippet: LNCaP cells were infected with lenti‐open reading frame particles encoding IL13RA2 GFP (Cat #: RC207672L4V) or a non‐targeted control GFP (Cat #: PS100093V) (Origene, Rockville, MD) using 5 μg/ml polybrene (Sigma).

Techniques: Expressing, Control, Real-time Polymerase Chain Reaction, Western Blot

Journal: Cancer Reports

Article Title: Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models

doi: 10.1002/cnr2.1701

Figure Lengend Snippet: IL13Rα2 overexpression in LNCaP cells enhanced proliferation in androgen‐depleted medium. A. Expression of IL13RA2 mRNA (based on GAPDH) in LNCaP‐mock and LNCaP‐IL13Rα2 by real‐time PCR (** p < 0.005). B. Expression of IL13Rα2 protein (based on α‐tubulin) in LNCaP‐mock and LNCaP‐IL13Rα2 by western blotting. C. Cell numbers of LNCaP‐mock and LNCaP‐IL13Rα2 after 72 h in normal medium (FBS) with or without human IL13 recombinant protein (25 ng/ml) (* p < 0.05). D. Cell numbers of LNCaP‐mock and LNCaP‐IL13Rα2 after 72 h in androgen‐depleted medium (CSFBS) with or without human IL13 recombinant protein (* p < 0.05, ** p < 0.005)

Article Snippet: LNCaP cells were infected with lenti‐open reading frame particles encoding IL13RA2 GFP (Cat #: RC207672L4V) or a non‐targeted control GFP (Cat #: PS100093V) (Origene, Rockville, MD) using 5 μg/ml polybrene (Sigma).

Techniques: Over Expression, Expressing, Real-time Polymerase Chain Reaction, Western Blot, Recombinant

Journal: Cancer Reports

Article Title: Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models

doi: 10.1002/cnr2.1701

Figure Lengend Snippet: Patient characteristics in the groups of IL13Ra2 staining levels

Article Snippet: LNCaP cells were infected with lenti‐open reading frame particles encoding IL13RA2 GFP (Cat #: RC207672L4V) or a non‐targeted control GFP (Cat #: PS100093V) (Origene, Rockville, MD) using 5 μg/ml polybrene (Sigma).

Techniques: Staining

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: Scratching significantly upregulates the expression of IL13RA2 in NHEK cells. A confluent keratinocyte culture was scratched with 14 lines, and the expression of IL13RA2 , IL4R , and IL13RA1 was analyzed by qRT-PCR and normalized to that of β-actin. Scratching significantly increased IL13RA2 expression in NHEK cells ( A ). IL4R ( B ) and IL13RA1 ( C ) expression was not altered. The cells were incubated for 6 h after scratching. Data is shown as the mean ± SEM ( n = 3). *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing, Quantitative RT-PCR, Incubation

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: Time-course study for IL13RA2 ( A ), IL4R ( B ), and IL13RA1 ( C ) expression. The gene expression of IL13RA2 , IL4R , and IL13RA1 was measured with or without scratching at 0, 3, 6, 9, 12, and 24 h ( n = 3). Data is shown as the mean ± SEM. ns: not significant. *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing, Gene Expression

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: Scratching upregulated IL13RA2 expression in a scratch line number-dependent manner. The keratinocyte sheet was scratched with 7, 14, and 18 scratch lines, and the gene expression of IL13RA2 ( A ), IL4R ( B ), and IL13RA1 ( C ) was measured ( n = 3) 6 h after scratching. Data is shown as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing, Gene Expression

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: The effect of IL-13 on scratch-induced IL13RA2 ( A ), IL4R ( B ), and IL13RA1 ( C ) expression. Confluent keratinocyte sheets were non-scratched or scratched with 18 lines in the presence or absence of graded IL-13 concentrations (1, 5, 10 ng/mL). Cells were treated with IL-13 for 14 h before scratching and then incubated for another 6 h. Data is shown as the mean ± SEM. * p < 0.05, *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing, Incubation

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: The effect of MAPK inhibitors on IL13RA2 ( A ), IL4R ( B ), and IL13RA1 ( C ) expression. Non-scratched and scratched confluent keratinocytes were treated with or without U0126 (MEK 1/2-ERK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38MAPK inhibitor). Data is shown as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing

Journal: International Journal of Molecular Sciences

Article Title: Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

doi: 10.3390/ijms20133324

Figure Lengend Snippet: IL13RA2 expression was upregulated in the IL-13Rα2-Tg-HaCaT cells more than in control Moc-HaCaT cells ( A ). Upregulated IL-13Rα2 protein expression was observed in the IL-13Rα2-Tg-HaCaT cells, compared to that in Moc-HaCaT cells ( B ). IL-13-induced IVL downregulation was partially restored in IL-13Rα2-Tg-HaCaT cells ( C ). ** p < 0.01, *** p < 0.001.

Article Snippet: Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone were obtained from Origene Technologies (Rockville, MD, USA).

Techniques: Expressing, Control

Journal: Cancer Research

Article Title: Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies

doi: 10.1158/0008-5472.can-07-1493

Figure Lengend Snippet: Figure 1. Analysis of oligonucleotide microarray data for IL13Ra2 gene expression. A, Tukey box plot comparing the natural log of the MAS5 expression values of IL13Ra2 in nonneoplastic brain control (green) and glioblastoma multiforme (GBM; red) samples. Boxes, interquartile range of expression values. The whiskers extend to the highest and lowest values of expression that are not considered outliers. Circles, outliers. B, XY scatterplot of expression levels of individual samples. X axis, individual control (green) or glioblastoma multiforme (red) sample; Y axis, natural log of the MAS5 IL13Ra2 expression level of the represented sample. The solid line indicates the mean expression level of the controls and the hashed line indicates two SDs above this value. Samples that lie above this line are considered to exhibit significantly greater expression of IL13Ra2 than the controls. C, sample density distribution plot comparing the natural log of the MAS5 expression levels of IL13Ra2 in nonneoplastic brain control (green) and glioblastoma multiforme (red) samples. For a given IL13Ra2 gene expression value (X axis), the relative density of samples is represented by the density estimate (Y axis). For all panels, MAS5 Expression denotes the expression values derived from the Affymetrix suite version 5 software.

Article Snippet: To show the specificity of the goat anti-IL13Ra2 polyclonal antibodies, 293FT human embryonic kidney cells (Invitrogen) stably transfected with an IL13Ra2 cDNA (Origene) and nontransfected control 293FT cells were stained and imaged as described.

Techniques: Microarray, Gene Expression, Expressing, Control, Derivative Assay, Software

Journal: Cancer Research

Article Title: Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies

doi: 10.1158/0008-5472.can-07-1493

Figure Lengend Snippet: Figure 3. IL13Ra2 expression as determined by immunohistochemical staining. A to D, expression of IL13Ra2 in paraffin-embedded sections of nonneoplastic brain white matter (A) and paraffin-embedded sections of glioblastoma multiforme tumors (B–D). Representative glioblastoma multiforme tumor sections with high (B), mixed (C), and negative (D) IL13Ra2 expression. Anti-IL13Ra2 antibody staining (green) and DAPI staining of nuclei (blue). Bar, 50 Am.

Article Snippet: To show the specificity of the goat anti-IL13Ra2 polyclonal antibodies, 293FT human embryonic kidney cells (Invitrogen) stably transfected with an IL13Ra2 cDNA (Origene) and nontransfected control 293FT cells were stained and imaged as described.

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Cancer Research

Article Title: Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies

doi: 10.1158/0008-5472.can-07-1493

Figure Lengend Snippet: Figure 2. QRT-PCR results for expression of IL13Ra2 in patient samples of glioblastoma multiforme (black columns) and nonneoplastic brain control (white columns). Y axis, natural log of the fold increase in IL13Ra2 expression level of a particular sample relative to the mean IL13Ra2 expression level of the nonneoplastic brain samples. Horizontal solid line, mean IL13Ra2 expression of the nonneoplastic brain samples. Samples with fold expression levels above the hashed line show significantly higher IL13Ra2 expression than the mean expression level of the nonneoplastic brain samples.

Article Snippet: To show the specificity of the goat anti-IL13Ra2 polyclonal antibodies, 293FT human embryonic kidney cells (Invitrogen) stably transfected with an IL13Ra2 cDNA (Origene) and nontransfected control 293FT cells were stained and imaged as described.

Techniques: Quantitative RT-PCR, Expressing, Control

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 2. Periodic acid-Schiff’s (PAS) staining (a–h) and MUC5AC immunohistochemical staining (i–p) of normal human bronchial epithelial cells (NHBECs) incubated at the air–liquid interface with IL-13 (10 ng/mL) (a, b, d, f, g, i, j, l, n, o, q) or vehicle (PBS) (c, e, h, k, m, p) for 14 days in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL) (b, c, j, k), an anti-IL-13Ra2 antibody (2.5 mg/mL) (d, e, l, m), an anti-IgG1 isotype control antibody (10 m g/mL) (f, n) or recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) (g, h, o, p). None of the cells were positive after treatment with IL-13 (10 ng/mL) in the absence of the first antibody (q). White arrowheads show PAS-positive goblet cells (a, d, f). Black arrowheads show MUC5AC-positive cells (i, l, n, o). The goblet cells with secretory granules stained clearly with the PAS staining method. On the other hand, there were also surface cells that did not have any goblet cell granules but were stained with PAS, PAS-positive-but-not-goblet cells. Scale bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Immunohistochemical staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 3. Number of periodic acid-Schiff’s (PAS) staining positive cells (a, PAS-positive cells), goblet cells (b), MUC5AC staining positive cells (c, MUC5AC- positive cells) and total cells (d) of normal human bronchial epithelial cells incubated with either IL-13 (10 ng/mL), IL-4 (1 ng/mL) or vehicle (PBS) for 14 days at the air–liquid interface, in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL), an anti-IL-13Ra2 antibody (2.5 mg/mL), an anti-IgG1 isotype control antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL). Results are means SEM from five different bronchi. Significant differences from PBS alone are Po0.05, Po0.01 and Po0.001. Significant differences from IL-13 alone are 1Po0.05, 11Po0.01 and 111Po0.001.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 4. Periodic acid-Schiff’s (PAS) staining (a, b) and MUC5AC immunohistochemical staining (c–e) of normal human bronchial epithelial cells incubated at the air–liquid interface with IL-4 (1 ng/mL) (a–e) for 14 days in the presence of recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/ mL) (b, d). None of the cells were positive after treatment with IL-13 (10 ng/mL) in the absence of the first antibody (e). White arrowheads show PAS- positive goblet cells (a, b). Black arrowheads show MUC5AC-positive cells (c, d). Scale bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Immunohistochemical staining, Incubation, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 6. (a) and (b) Time course of mRNA expression of MUC5AC (a) and IL-13Ra2 (b) in normal human bronchial epithelial cells cultured with IL-13 (10 ng/mL). The results are the mean SEM from 14 different bronchi. Significant differences from values on day 0 are indicated by Po0.05, Po0.02, Po0.005.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Expressing, Cell Culture

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 5. MUC5AC protein concentrations in the supernatants of normal human bronchial epithelial cell treated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) in the presence or in the absence of either an anti-IL-13Ra1 antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) for 14 days. Data are expressed as percent above control vehicle (PBS). The results are mean SEM from three different bronchi. Significant differences from PBS alone are indicated by Po0.05. Significant differences from IL-13 alone are 1Po0.05.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Recombinant, Control

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 7. (a) and (b) The amount of MUC5AC mRNA expression in normal human bronchial epithelial cells (NHBECs) incubated with IL-13 (10 ng/mL) or vehicle of IL-13 (PBS) in the presence of an anti-IL-13Ra1 antibody (10 mg/mL) (a), an anti-IL-13Ra2 antibody (2.5 mg/mL) (b), an anti-IgG1 isotype control antibody (10 mg/mL) or a vehicle of antibodies (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) are Po0.01. Significant differences from IL-13 alone are 1Po0.05. (c) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-13 (10 ng/mL) or a vehicle of IL-13 (PBS) in the presence of recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) Po0.01. Significant differences from IL-13 alone are indicated by 1Po0.05 and 11Po0.01. (d) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-4 (0.1, 1 or 10 ng/mL) or a vehicle of IL-4 (PBS) in the presence of rsIL-13Ra2 (4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are mean SEM from five different bronchi. Significant differences from the vehicle of IL-4 (PBS) (control) are Po0.01 and Po0.05.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Expressing, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 8. Immunohistochemical staining of normal human bronchial epithelial cells (NHBECs) for IL-13Ra2 proteins after exposure to PBS (a, vehicle of IL-13) or IL-13 (10 ng/mL) (b, c) for 14 days in the presence (a, b) or in the absence (c) of the first antibody. Weak staining of IL-13Ra2 protein (white arrowheads) was observed 14 days after adding the vehicle of IL-13 (PBS) (a). In contrast, the potency of IL-13Ra2 protein staining increased in NHBECs 14 days after adding IL-13 (10 ng/mL) (b) with strong staining of IL-13Ra2 protein in some cells (black arrowheads). Arrows shows goblet cells (b, c). Bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Immunohistochemical staining, Staining

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 9. (a) Time course of a soluble form of IL-13Ra2 proteins concentrations in the supernatants of normal human bronchial epithelial cells (NHBECs) cells after adding IL-13 (10 ng/mL). The results are mean SEM from four different bronchi. Significant differences from values on day 0 arePo0.05. (b) Time course of IL-13Ra2 proteins in lysates of NHBECs after adding IL-13 (10 ng/mL). The results are the mean SEM from four different bronchi. (c) A Western blot analysis of IL-13Ra2 protein in the culture supernatants (lane 1–4) and the cell lysates (lane 6) of NHBECs incubated with IL-13 (10 ng/mL) for 21 days. Lanes shows samples before (day 0, lane 1), and 7 days (day 7, lane 2), 14 days (day 14, lanes 3 and 6) and 21 days (day 21, lane 4) after adding IL-13. The recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 100 ng) is immunoblotted as a positive loading sample (lane 5). The arrow (56 kDa) shows IL-13Ra2. Data are representative of three different experiments.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Western Blot, Incubation, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 10. Western blot analysis of signal transducer and activator of transcription 6 (STAT6) (a) and the phosphorylated, active form of STAT6 (p-STAT6) (b) in the cell lysates of normal human bronchial epithelial cells incubated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) for 14 days. Lanes show the data from samples treated with either the vehicle of IL-13 or IL-4 (PBS) (lane 1), IL-13 (10 ng/mL) plus the vehicle of antibody (PBS) (lane 2), IL-13 plus anti-IL-13Ra1 antibody (10 mg/mL) (lane 3), IL-13 plus recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 ng/mL) (lane 4), IL-4 (1 ng/mL) plus the vehicle of antibody (PBS) (lane 5) or with IL-4 (1 ng/mL) plus rsIL-13Ra2 (4 ng/mL) (lane 6). The arrows show STAT6 (a) and p-STAT6 (b) (100120 kDa). Data are representative of three differ- ent experiments.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Western Blot, Incubation, Recombinant